Secukinumab is a fully human anti-interleukin-17A monoclonal antibody. Determine the efficacy, safety and usability of secukinumab administered via autoinjector/pen. This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg, 150 mg or placebo self-injection once weekly to Week 4, then every 4 weeks. Co-primary end points at Week 12 were ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) and clear/almost clear skin by investigator's global assessment 2011 modified version (IGA mod 2011 0/1). Secondary end points included autoinjector usability, assessed by successful, hazard-free self-injection and subject-reported acceptability on Self-Injection Assessment Questionnaire. Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with secukinumab 300 mg (86.7% and 73.3%, respectively) and 150 mg (71.7% and 53.3%, respectively) vs. placebo (3.3% and 0%, respectively) (P < 0.0001 for all). All subjects successfully self-administered treatment at Week 1, without critical use-related hazards. Subject acceptability of autoinjector was high throughout 12 weeks. Adverse events were higher with secukinumab (300 mg, 70.0%; 150 mg, 63.9%) vs. placebo (54.1%), with differences largely driven by mild/moderate nasopharyngitis. Secukinumab delivered by autoinjector/pen is efficacious, well-tolerated and associated with high usability in moderate to severe plaque psoriasis.
Secukinumab is a fully human anti - interleukin-17A monoclonal antibody . Determine the efficacy , safety and usability of secukinumab administered via autoinjector / pen . This phase III trial randomized subjects with moderate to severe plaque psoriasis to secukinumab 300 mg , 150 mg or placebo self - injection once weekly to Week 4 , then every 4 weeks . Co - primary end points at Week 12 were ≥75 % improvement in Psoriasis Area and Severity Index ( PASI 75 ) and clear / almost clear skin by investigator 's global assessment 2011 modified version ( IGA mod 2011 0/1 ) . Secondary end points included autoinjector usability , assessed by successful , hazard - free self - injection and subject - reported acceptability on Self - Injection Assessment Questionnaire . Week 12 PASI 75 and IGA mod 2011 0/1 responses were superior with secukinumab 300 mg ( 86.7 % and 73.3 % , respectively ) and 150 mg ( 71.7 % and 53.3 % , respectively ) vs. placebo ( 3.3 % and 0 % , respectively ) ( P < 0.0001 for all ) . All subjects successfully self - administered treatment at Week 1 , without critical use - related hazards . Subject acceptability of autoinjector was high throughout 12 weeks . Adverse events were higher with secukinumab ( 300 mg , 70.0 % ; 150 mg , 63.9 % ) vs. placebo ( 54.1 % ) , with differences largely driven by mild / moderate nasopharyngitis . Secukinumab delivered by autoinjector / pen is efficacious , well - tolerated and associated with high usability in moderate to severe plaque psoriasis .
Which molecule is targeted by a monoclonal antibody Secukinumab?
Which molecule is targeted by a monoclonal antibody Secukinumab ?
interleukin-17A
interleukin-17A